Exelixis, Inc. (EXEL)
59.86
+0.84
(+1.42%)
USD |
NASDAQ |
Oct 09, 16:00
59.85
-0.01
(-0.02%)
After-Hours: 20:00
Exelixis Free Cash Flow (Quarterly) : 300.92M for June 30, 2026
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 300.92M |
| March 31, 2026 | 250.34M |
| December 31, 2025 | 332.36M |
| September 30, 2025 | 288.84M |
| June 30, 2025 | 46.16M |
| March 31, 2025 | 208.48M |
| December 31, 2024 | 236.29M |
| September 30, 2024 | 263.14M |
| June 30, 2024 | 112.98M |
| March 31, 2024 | 59.13M |
| December 31, 2023 | -2.564M |
| September 30, 2023 | 107.99M |
| June 30, 2023 | 115.04M |
| March 31, 2023 | 72.38M |
| December 31, 2022 | 71.98M |
| September 30, 2022 | 102.03M |
| June 30, 2022 | 18.79M |
| March 31, 2022 | 142.11M |
| December 31, 2021 | 80.49M |
| September 30, 2021 | 68.81M |
| June 30, 2021 | 161.29M |
| March 31, 2021 | 25.99M |
| December 31, 2020 | 19.00M |
| September 30, 2020 | 11.81M |
| June 30, 2020 | 94.71M |
| Date | Value |
|---|---|
| March 31, 2020 | 53.11M |
| December 31, 2019 | 150.76M |
| September 30, 2019 | 73.56M |
| June 30, 2019 | 130.52M |
| March 31, 2019 | 159.29M |
| December 31, 2018 | 101.70M |
| September 30, 2018 | 149.33M |
| June 30, 2018 | 62.53M |
| March 31, 2018 | 68.86M |
| December 31, 2017 | 35.66M |
| September 30, 2017 | 36.73M |
| June 30, 2017 | 4.027M |
| March 31, 2017 | 68.05M |
| December 31, 2016 | 83.13M |
| September 30, 2016 | -8.527M |
| June 30, 2016 | -26.14M |
| March 31, 2016 | 156.13M |
| December 31, 2015 | -35.77M |
| September 30, 2015 | -34.25M |
| June 30, 2015 | -26.90M |
| March 31, 2015 | -45.12M |
| December 31, 2014 | -50.00M |
| September 30, 2014 | -58.11M |
| June 30, 2014 | -55.30M |
| March 31, 2014 | -72.47M |
Free Cash Flow Definition
Free Cash Flow is the cash a company has left after paying for its day-to-day operations and investing in its physical assets, such as buildings, equipment and technology. The company can use that cash however it chooses: paying dividends, buying back shares, paying down debt, making acquisitions or keeping it for future growth.
Free Cash Flow (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow (Quarterly) Benchmarks
| Alnylam Pharmaceuticals, Inc. | 292.04M |
| BioMarin Pharmaceutical, Inc. | 133.86M |
| Cytokinetics, Inc. | -164.17M |
| Emergent BioSolutions, Inc. | 54.00M |
| Gilead Sciences, Inc. | 3.433B |